Skip to content
Screener

Lexicon Pharmaceuticals LXRX Business Segments — Cost of Sales

Similar metrics at other companies

Target logo
TGTReportable Segment — Cost of Sales
$18.06B+5.4%
Indivior Pharmaceuticals, Inc. logo
INDVReportable Segment — Cost of Sales
$40M-9.1%
VGN
VGNTReportable Segment — Cost of Sales
$1.97B+10.9%
ITG
ITGRReportable Segment — Cost of Sales
$338.31M+7.6%
ImmunityBio, Inc. logo
IBRXReportable Segment — Cost of Sales
$238K+310%
SharkNinja logo
SNReportable Segment — Cost of Sales
$905.14M+22.9%

Other financials

Income statement

See full
Revenue$692.0K-97.6%
Gross profit$653.0K-97.7%
Operating income-$26.5M-810%
Net income-$31.8M-1,077%
EPS (diluted)-$0.07-800%

Balance sheet

See full
Cash & equivalents$40.9M-18.7%
Total debt$59.2M-3.6%
Total equity$174.5M+34.8%
Total assets$250.1M+10.9%

Cash flow

See full
Operating cash flow-$9.2M
CapEx--100%
Free cash flow-$17.2M+21.5%

Valuation

See full
Market cap$1.1B+191%
Enterprise value$1.12B+187%
P/S26.5×+20.0×

Profitability

See full
Gross margin99.1%0.0pp
Operating margin-131.4%-34.2pp
Net margin-147.4%-32.8pp
FCF margin-578.5%-283pp

Returns & leverage

See full
Return on equity-40.2%-11.2pp
Debt / equity0.3×-0.1×
Current ratio13.4×+9.2×

Where this comes from

Reported directly by Lexicon Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.

The source filing: Lexicon Pharmaceuticals’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001062822-26-000117
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Royalties and other revenue1224
Total revenues69228,86621,79430,128
Operating expenses:
Cost of sales393314763
Research and development, including stock-based compensation of $1,384, $1,620, $2,753, and $3,194 respectively17,44315,74730,19931,050
Selling, general and administrative, including stock-based compensation of $1,952, $1,575, $3,661, and $3,044 respectively9,7509,35018,98420,958
Total operating expenses27,23225,13049,33052,071
(Loss) income from operations(26,540)3,736(27,536)(21,943)

Item 1. Financial Statements

FAQ

What is Lexicon Pharmaceuticals's business segments — cost of sales?
Lexicon Pharmaceuticals (LXRX) reported business segments — cost of sales of $39K in Q2 2026.
How has Lexicon Pharmaceuticals's business segments — cost of sales changed year-over-year?
Lexicon Pharmaceuticals's business segments — cost of sales increased by 18.2% year-over-year, from $33K to $39K.
What does business segments — cost of sales mean?
The direct costs attributable to the production and delivery of goods or services sold by the business segment. This includes raw materials, direct labor, and manufacturing overhead directly linked to revenue generation. Monitoring this metric helps assess the segment's gross margin efficiency and production cost control.

Ask your AI about Lexicon Pharmaceuticals's business segments — cost of sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude